17α,21-diacetoxy-11β-(4-acetylphenyl)19-norpregna-4,9-diene-3,20-dione | 365416-59-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 17α,21-diacetoxy-11β-(4-acetylphenyl)19-norpregna-4,9-diene-3,20-dione
• 英文别名: [2-[(8S,11R,13S,14S,17R)-17-acetyloxy-11-(4-acetylphenyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
• CAS: 365416-59-7
• 化学式: C₃₂H₃₆O₇
• 分子量: 532.634
• InChiKey: NLHPSDYWHNMKKT-WFZWGZKUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Compositions containing oils having a specific gravity higher than the specific gravity of water
  申请人：Lapidot Noa

  公开号：US20050037087A1

  公开（公告）日：2005-02-17

  The invention relates to pharmaceutical or cosmetic compositions preferably in the form of microcapsules or microparticles which include at least one active ingredient and an oil or a mixture of oils wherein the oil or mixture of oils alone or in combination with the active ingredient have a specific gravity higher than the specific gravity of water. The invention further relates to a process for preparing said compositions.

  本发明涉及制药或化妆品组合物，优选为微胶囊或微粒形式，包括至少一种活性成分和油或油混合物，其中油或油混合物单独或与活性成分组合具有比水的比重高的特性。本发明还涉及制备该组合物的方法。
• COMPOSITIONS CONTAINING OILS HAVING A SPECIFIC GRAVITY HIGHER THAN THE SPECIFIC GRAVITY OF WATER
  申请人：LAPIDOT Noa

  公开号：US20120321685A1

  公开（公告）日：2012-12-20

  The invention relates to pharmaceutical or cosmetic compositions preferably in the form of microcapsules or microparticles which include at least one active ingredient and an oil or a mixture of oils wherein the oil or mixture of oils alone or in combination with the active ingredient have a specific gravity higher than the specific gravity of water. The invention further relates to a process for preparing said compositions.

  本发明涉及制药或化妆品组合物，优选为微胶囊或微粒形式，其中包括至少一种活性成分和一种油或混合油，其中油或混合油单独或与活性成分结合具有比水的比重大的比重。本发明还涉及制备所述组合物的方法。
• 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
  申请人：The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services

  公开号：EP2033965A2

  公开（公告）日：2009-03-11

  The invention provides 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents.

  本发明提供了 17-α-取代-11-β-取代-4-芳基和 21-取代 19-前二烯酮作为抗孕激素制剂。
• 17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents
  申请人：The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

  公开号：EP2348030A2

  公开（公告）日：2011-07-27

  The invention provides 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienediones as antiprogestational agents.

  本发明提供了 17-α-取代-11-β-取代-4-芳基和 21-取代 19-前二烯酮作为抗孕激素制剂。
• COMPOSITIONS AND METHODS FOR NON-TOXIC DELIVERY OF CDB-2914
  申请人：Allergan Pharmaceuticals International Limited

  公开号：EP3865502A1

  公开（公告）日：2021-08-18

  The present invention relates to a pharmaceutical composition comprising 17.alpha.-acetoxy-11.beta.-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione (CDB-2914) for use in treating endometriosis or pain associated therewith, or uterine fibroids, by daily administration of 5 mg to 20 mg thereof to the vaginal mucosa of a female patient in need thereof for a period of at least 4 months. CDB-2914

  本发明涉及一种药物组合物，该药物组合物包含17.α.-乙酰氧基-11.β.-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮（CDB-2914），用于治疗子宫内膜异位症或与之相关的疼痛，或子宫肌瘤，方法是每天向有需要的女性患者的阴道粘膜给药5毫克至20毫克，持续至少4个月。 CDB-2914